Special Issue

Advanced Liposomes for Drug Delivery

Message from the Guest Editors

Liposomes are phospholipid-based nanostructures discovered in the early 1960s; they have been extensively discussed as drug delivery systems since 1976. The approval of DOXILTM, a doxorubicin liposomal formulation, in 1995, encouraged researchers to reach better outcomes regarding the safety and therapeutic efficacy of liposomes. In the last several decades, liposomes with several lipid compositions and surface modifications, and with the most extensive list of different kinds of encapsulated molecules (e.g., drugs, peptides, antibodies, nucleic acids) have been reported for most types of applications. However, the versatility of liposomes and their key role in health care technology advances continue to encourage research groups to develop new liposomal formulations. This Special Issue aims to present the new advances in liposome research and the current evidence of liposome use as drug delivery systems in the treatment and diagnosis of cancer, inflammation, or infectious disease. We look forward to receiving your contributions.

Guest Editors

Dr. Juliana De Oliveira Silva

Department of Pharmaceutical Products, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, Belo Horizonte 31270-901, Brazil

Dr. Caroline Mari Ramos Oda

Department of Pharmaceutical Products, Faculty of Pharmacy, Federal University of Minas Gerais, UFMG, Belo Horizonte 31270-901, Brazil

Deadline for manuscript submissions

closed (30 November 2023)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 4.9 CiteScore 7.9 Indexed in PubMed



mdpi.com/si/137387

Pharmaceutics MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 pharmaceutics@mdpi.com

mdpi.com/journal/ pharmaceutics





an Open Access Journal by MDPI

Impact Factor 4.9 CiteScore 7.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).

